双歧杆菌三联活菌肠溶胶囊预防小儿肺炎继发腹泻180例临床观察  

Clinical Study on 180 Cases of Prophylactic Treatment with Bifid Triple Viable Enteric-coated Capsules for Preventing Children Diarrhea after Pneumonia

作　　者：张赤[1] 彭罕鸣[1] 曹晓晓[1] 吴宁[1] 

机构地区：[1]武汉市妇女儿童医疗保健中心,武汉市430016

出　　处：《中国药房》2010年第18期1687-1689,共3页China Pharmacy

摘　　要：目的:观察双歧杆菌三联活菌肠溶胶囊预防小儿肺炎继发腹泻的临床效果。方法:将360例小儿肺炎患儿随机分为2组,以住院期间抗生素治疗同时应用双歧杆菌三联活菌肠溶胶囊的患儿为治疗组(180例),仅使用抗生素治疗的患儿为对照组(180例),分别观察治疗第3、5、7天时腹泻的发生率及严重程度。结果:治疗第3、5、7天时腹泻的发生率,治疗组分别为10.00%、16.67%、13.33%,对照组分别为36.67%、43.33%、50.00%,2组间比较差异均具有统计学意义(P<0.01);治疗组与对照组轻型腹泻发生率分别为13.33%、23.33%(P<0.05),重型腹泻发生率分别为3.33%、26.67%(P<0.01),无腹泻发生率分别83.33%、50.00%(P<0.01)。治疗组病例依从性较好,未见不良事件,全部完成本次临床观察。结论:双歧杆菌三联活菌肠溶胶囊能降低小儿肺炎继发腹泻的发生率。OBJECTIVE： To observe clinical efficacy of Bifid tripie viable enteric-coated capsules in the treatment of children diarrhea after pneumonia. METHODS： 360 cases of children pneumonia were randomly divided into two groups. Treatment group were treated with antibiotics and Bifid triple viable enteric-coated capsules in duration of hospital stay（n=180）. Control group were treated with antibiotics only （n=180）. The incidence and severity of diarrhea in two groups were observed at the 3rd, 5th, 7th of therapy. RESULTS： The incidence of diarrhea at the 3rd, 5th, 7th of therapy in treatment group were 10.00%,16.67% and 13.33%, in control group 36.67%, 43.33% and 50.00%, with statistically significance（P0.01）. The difference of mild diarrhea of two groups were 13.33% and 23.33%, severe diarrhea 3.33% and 26.67%, and none of diarrhea were 83.33% and 50.00%respectively （P0.01）. There were no cases of adverse events in treatment group with good compliance and clinical observation of treatment group was completed throughly. CONCLUSION： Bifid triple viable enteric-coated capsules can reduce the incidence of children diarrhea after pneumonia.

关 键 词：小儿 肺炎 腹泻 双歧杆菌三联活菌肠溶胶囊 预防 

分 类 号：R975[医药卫生—药品] R985[医药卫生—药学]